Sign In
Buy VNDA
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
01:11pm, Monday, 06'th Jan 2025
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
Nvidia stock inflows reach $30B: Vanda Research
01:30pm, Friday, 27'th Dec 2024
Retail investors flocked to Nvidia (NVDA) in 2024. According to Vanda Research, the chip giant saw nearly $30 billion in inflows during the year.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
08:50am, Tuesday, 24'th Dec 2024
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
01:26pm, Friday, 20'th Dec 2024
Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul
WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-184
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
09:29pm, Monday, 16'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' poss
New Strong Buy Stocks for November 14th
07:00am, Thursday, 14'th Nov 2024
VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
04:58pm, Tuesday, 12'th Nov 2024
WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in Novembe
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
08:20pm, Wednesday, 06'th Nov 2024
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
04:02pm, Wednesday, 06'th Nov 2024
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges Fanapt® launch in bipola
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
04:45pm, Monday, 04'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
11:00am, Saturday, 02'nd Nov 2024
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advis
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
02:05pm, Friday, 01'st Nov 2024
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
08:00pm, Thursday, 31'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are a
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
04:30pm, Wednesday, 30'th Oct 2024
Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 o
